Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant
threat to public health worldwide. The purpose of this study was to review current evidence …

The current standard treatment for chronic hepatitis C consists of the combination of
pegylated interferon and ribavirin. Although interferon is known to have potent antiviral …

Hepatitis C virus (HCV) chronically infects 3% of the world's population, and complications
from HCV are the leading indication for liver transplantation. Given the need for better anti …

Hepatitis C virus (HCV) infection blocks cellular interferon (IFN)‐mediated antiviral signaling
through cleavage of Cardif by HCV‐NS3/4A serine protease. Like NS3/4A, NS4B protein …

Background & Aims: Cyclosporin A specifically suppresses hepatitis C virus (HCV)
replication in vitro at clinically achievable concentrations. In this study, we investigated the …

Interferons (IFNs) and the interferon‐stimulated genes (ISGs) play a central role in antiviral
responses against hepatitis C virus (HCV) infection. We have reported previously that ISGs …

We report here a biochemical and structural characterization of domain 2 of the
nonstructural 5A protein (NS5A) from the JFH1 Hepatitis C virus strain and its interactions …

Despite recent advances in the treatment of hepatitis C, the quest for pan-genotype,
effective, and well-tolerated inhibitors continues. To facilitate these efforts, it is desirable to …

Chronic hepatitis C virus (HCV) infection affects more than 170 million persons worldwide
and is responsible for the development of liver cirrhosis in many cases. Standard treatment …

Background Autophagy has been reported to play a pivotal role on the replication of various
RNA viruses. In this study, we investigated the role of autophagy on hepatitis C virus (HCV) …